Username Password
S&P 500: 1,343.88 Change: -0.08%

PROGEN PHARMACEUTICALS LTD (PGLA)

Overview
Price 0.15
Price Change Today +$0.03 (+25.00%)
P&P rating Rating: 2
Zacks Rank N/A - N/A
Open Price $0.14
Previous Close $0.12
Daily Range $0.14 - $0.15
52-Week Range $0.12 - $0.35
Volume 12,400
chart
Progen Pharmaceuticals Limited is an Australian-based globally focused biotechnology company committed to the discovery, development and commercialisation of small molecule therapeutics primarily for the treatment of cancer. The company has an intimate understanding of the role of heparan sulfate, a complex sugar, in cancer disease processes and have developed a small-molecule drug development program in this area. PI-88 is the first product produced from this research and promising signs of efficacy in humans are emerging from the clinical program. A Phase II clinical trial program across multiple cancers is currently underway. Areas of investigation include lung cancer, primary liver cancer, multiple myeloma and melanoma and prostate cancer. This is supplemented by an innovative drug discovery program that intends to funnel future compounds through the pipeline and into human trials.
Other Resources for PGLA
zacks.com
Commentary
No Commentary Found for This Ticker.
Progen Pharmaceuticals Limited is an Australian-based globally focused biotechnology company committed to the discovery, development and commercialisation of small molecule therapeutics primarily for the treatment of cancer. The company has an intimate understanding of the role of heparan sulfate, a complex sugar, in cancer disease processes and have developed a small-molecule drug development program in this area. PI-88 is the first product produced from this research and promising signs of efficacy in humans are emerging from the clinical program. A Phase II clinical trial program across multiple cancers is currently underway. Areas of investigation include lung cancer, primary liver cancer, multiple myeloma and melanoma and prostate cancer. This is supplemented by an innovative drug discovery program that intends to funnel future compounds through the pipeline and into human trials.
 
No brokerage coverage for PGLA
 
PGLA Ratings:BUY  SELL  HOLD
PGLA Consensus Forecasts
Rate this Stock!
You haven't rated this stock yet!

What The Community Thinks

Total Players

5 Buy
1 Sell
 
Top Buy Analysis
No Buy Analysis. Be the First.

Top Sell Analysis
No Sell Analysis. Be the First.
Blog Posts
No related Blog Posts.
Commentary
BUY: PROGEN PHARMACEUTICALS LIMITED (PGLA) Rating: 2
Start Price: $6.79
Points: -89.25
Created: 01/01/2008

Comments: 0 | Comment

Recs:
 
SELL: PROGEN PHARMACEUTICALS LIMITED (PGLA) Rating: 2
Start Price: $6.79
Points: +89.25
Created: 01/01/2008

Comments: 0 | Comment

Recs:
 
BUY: PROGEN PHARMACEUTICALS LIMITED (PGLA) Rating: 2
Start Price: $5.78
Points: -88.85
Created: 01/01/2008

Comments: 0 | Comment

Recs:
 
BUY: PROGEN PHARMACEUTICALS LIMITED (PGLA) Rating: 2
Start Price: $5.30
Points: -88.60
Created: 01/01/2008

Comments: 0 | Comment

Recs:
 
BUY: PROGEN PHARMACEUTICALS LIMITED (PGLA) Rating: 2
Start Price: $5.79
Points: -88.85
Created: 01/01/2008

Comments: 0 | Comment

Recs:
 
BUY: PROGEN PHARMACEUTICALS LIMITED (PGLA) Rating: 2
Start Price: $4.85
Points: -88.33
Created: 01/01/2008

Comments: 0 | Comment

Recs:
 
Picks
Username P&P Score Call Time Frame Start Date Start Price Today (change) Stock Gain S&P Gain Points Analysis
oldpops 33.75 BUY Six Months to a Year 01/01/2008 $6.79 $0.16
(0.00%)
-97.70% -8.45% -89.25
Ohscott 52.92 SELL Six Months to a Year 01/01/2008 $6.79 $0.16
(0.00%)
-97.70% -8.45% +89.25
MRESTING 72.14 BUY Six Months to a Year 01/01/2008 $5.78 $0.16
(0.00%)
-97.30% -8.45% -88.85
Ramv 20.87 BUY Six Months to a Year 01/01/2008 $5.30 $0.16
(0.00%)
-97.06% -8.45% -88.60
knuckking 72.14 BUY Six Months to a Year 01/01/2008 $5.79 $0.16
(0.00%)
-97.31% -8.45% -88.85
legolask BUY Six Months to a Year 01/01/2008 $4.85 $0.16
(0.00%)
-96.78% -8.45% -88.33
Sponsored Links